In a recent press release the company outlines that approximately 17,000 patients are currently on the US liver transplant waiting list, with only 6,000 liver transplants performed each year. With a market opportunity of over $ 3 billion, Organovo intends to submit an Investigational New Drug application to the US Food and Drug Administration for its therapeutic liver tissue in three to five years. The development will focus on two initial areas: acute-on-chronic-liver failure in patients with liver disease and paediatric metabolic liver diseases, where bioprinted liver tissue patches might show therapeutic benefits.